U.S. Markets closed

Is It Too Late To Buy Agile Therapeutics Inc (AGRX)?

Thomas Auclair

Agile Therapeutics Inc (NASDAQ:AGRX), a pharmaceuticals company based in United States, received a lot of attention from a substantial price increase on the NasdaqGM in the over the last few months. With many analysts covering the stock, we may expect any price-sensitive announcements have already been factored into the stock’s share price. But what if there is still an opportunity to buy? Let’s take a look at AGRX’s outlook and value based on the most recent financial data to see if the opportunity still exists. See our latest analysis for AGRX

What is AGRX worth?

Good news, investors! AGRX is still a bargain right now. My valuation model shows that the intrinsic value for the stock is $46.8, which is above what the market is valuing the company at the moment. This indicates a potential opportunity to buy low. However, given that AGRX’s share is fairly volatile (i.e. its price movements are magnified relative to the rest of the market) this could mean the price can sink lower, giving us another chance to buy in the future. This is based on its high beta, which is a good indicator for share price volatility.

Can we expect growth from AGRX?

NasdaqGM:AGRX Future Profit Dec 2nd 17

Future outlook is an important aspect when you’re looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let’s also take a look at AGRX future expectations. AGRX’s earnings over the next few years are expected to increase by 94.11%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value.

What this means for you:

Are you a shareholder? Since AGRX is currently undervalued, it may be a great time to accumulate more of your holdings in the stock. With an optimistic outlook on the horizon, it seems like this growth has not yet been fully factored into the share price. However, there are also other factors such as capital structure to consider, which could explain the current undervaluation.

Are you a potential investor? If you’ve been keeping an eye on AGRX for a while, now might be the time to enter the stock. Its buoyant future outlook isn’t fully reflected in the current share price yet, which means it’s not too late to buy AGRX. But before you make any investment decisions, consider other factors such as the strength of its balance sheet, in order to make a well-informed buy.

Price is just the tip of the iceberg. Dig deeper into what truly matters – the fundamentals – before you make a decision on Agile Therapeutics. You can find everything you need to know about AGRX in the latest infographic research report. If you are no longer interested in Agile Therapeutics, you can use our free platform to see my list of over 50 other stocks with a high growth potential.


To help readers see pass the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned.